3-(3-chloro-2-methylphenyl)propene | 149553-92-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-chloro-2-methylphenyl)propene
• 英文别名: 1-chloro-2-methyl-3-prop-2-enylbenzene
• CAS: 149553-92-4
• 化学式: C₁₀H₁₁Cl
• mdl: MFCD11111041
• 分子量: 166.65
• InChiKey: YRLIBEBJLMFTLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  3-(3-chloro-2-methylphenyl)propene 在 sodium hydroxide 、 sodium tetrahydroborate 、 jones' reagent 、 mercury(II) diacetate 、 水 作用下， 以 丙酮 为溶剂， 反应 2.5h， 生成 1-(3-氯-2-甲基苯基)丙烷-1-酮
  参考文献：
  名称：

  Synthesis and Diatropicity of trans-2‘,5‘,10b,10c-Tetramethylfurano[3,4-e]-10b,10c-dihydropyrene. A Valence Isomerization To Form a Novel Isoannulenofuran at the Expense of Two Benzene and One Furan Rings

  摘要：

  The 1, 4-dicarbonyl compound 22 was prepared by an oxidative coupling of the benzyl methyl ketone 19. Dehydration of 22 gave the 3,4-diarylfuran 16 which upon functional group transformations and a subsequent intramolecular cyclization afforded only the anti isomer of the furanothiacyclophane 27. Ring contraction following a Wittig rearrangement-Hofmann elimination sequence led to the isolation of anti furanocyclophanene 15b. Valence isomerization of 15b to the isoannulenofuran 14b could be achieved either photochemically or thermally with 15b as the thermodynamically more stable isomer. Compound 14b was found to exhibit only a very small ring current. The diatropicity of 14b is clearly affected by a weak participation of the oxygen in pi-electron delocalization and a steric effect of its external methyl groups resulting in a deviation from planarity of its molecular periphery. The thermal conversion of 15b to 14b was determined to have a high activation energy of 114 kJ mol(-1). This thermal process, in addition to involving the disruption of jr-electron delocalization in two benzene and one furan rings, is another example of an unsual concerted, symmetry-forbidden reaction.

  DOI：

  10.1021/jo951586o
• 作为产物：
  描述：

  3-氯-2-甲基苯基氯化镁 、 3-溴丙烯 以 四氢呋喃 为溶剂， 反应 15.0h， 以79%的产率得到3-(3-chloro-2-methylphenyl)propene
  参考文献：
  名称：

  Synthesis and Diatropicity of trans-2‘,5‘,10b,10c-Tetramethylfurano[3,4-e]-10b,10c-dihydropyrene. A Valence Isomerization To Form a Novel Isoannulenofuran at the Expense of Two Benzene and One Furan Rings

  摘要：

  The 1, 4-dicarbonyl compound 22 was prepared by an oxidative coupling of the benzyl methyl ketone 19. Dehydration of 22 gave the 3,4-diarylfuran 16 which upon functional group transformations and a subsequent intramolecular cyclization afforded only the anti isomer of the furanothiacyclophane 27. Ring contraction following a Wittig rearrangement-Hofmann elimination sequence led to the isolation of anti furanocyclophanene 15b. Valence isomerization of 15b to the isoannulenofuran 14b could be achieved either photochemically or thermally with 15b as the thermodynamically more stable isomer. Compound 14b was found to exhibit only a very small ring current. The diatropicity of 14b is clearly affected by a weak participation of the oxygen in pi-electron delocalization and a steric effect of its external methyl groups resulting in a deviation from planarity of its molecular periphery. The thermal conversion of 15b to 14b was determined to have a high activation energy of 114 kJ mol(-1). This thermal process, in addition to involving the disruption of jr-electron delocalization in two benzene and one furan rings, is another example of an unsual concerted, symmetry-forbidden reaction.

  DOI：

  10.1021/jo951586o

文献信息

• 3-Isoxazolylphenyl compounds, their preparation and their use
  申请人：BASF Aktiengesellschaft

  公开号：US05256666A1

  公开（公告）日：1993-10-26

  3-Isoxazolylphenyl compounds Ia and Ib ##STR1## where R is halogen; alkyl; haloalkyl; alkoxy; haloalkoxy; alkenyl; haloalkenyl; unsubstituted or substituted phenylethenyl; alkynyl; cycloalkyl; aryl; hetaryl; CO.sub.2 R.sup.6 or CONR.sup.7 R.sup.8, R.sup.6 is hydrogen, alkyl, cycloalkyl or benzyl; R.sup.7 and R.sup.8 are each hydrogen, alkyl, cycloalkyl or benzyl or, together with the nitrogen atom to which they are bonded, form a heterocyclic radical; n is 0, 1 or 2; R.sup.1 is halogen or alkyl; R.sup.2 is hydrogen; alkyl; alkenyl; alkynyl or cyano; R.sup.3 and R.sup.4 independently of one another are each unsubstituted or substituted alkyl, alkenyl, cycloalkyl, phenyl, naphthyl, pyridyl or pyrimidinyl; or R.sup.3 and R.sup.4 together form unsubstituted or substituted alkylene; R.sup.5 is hydrogen; unsubstituted or substituted alkyl or one of the groups stated for R.sup.3 ; X is CH.sub.2, O, S or NR.sup.9 and R.sup.9 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl or unsubstituted or substituted benzyl, processes for their preparation, agents containing them and the use thereof.

  3-异噁唑基苯化合物Ia和Ib，其中R是卤素；烷基；卤代烷基；烷氧基；卤代烷氧基；烯基；卤代烯基；未取代或取代苯乙烯基；炔基；环烷基；芳基；杂芳基；CO.sub.2 R.sup.6或CONR.sup.7R.sup.8，R.sup.6是氢、烷基、环烷基或苄基；R.sup.7和R.sup.8分别是氢、烷基、环烷基或苄基，或者与它们结合的氮原子一起形成杂环基；n为0、1或2；R.sup.1是卤素或烷基；R.sup.2是氢；烷基；烯基；炔基或氰基；R.sup.3和R.sup.4彼此独立地是未取代或取代的烷基、烯基、环烷基、苯基、萘基、吡啶基或嘧啶基；或者R.sup.3和R.sup.4一起形成未取代或取代的烷基烯基；R.sup.5是氢；未取代或取代的烷基或R.sup.3所述的基之一；X是CH.sub.2、O、S或NR.sup.9，R.sup.9是氢、烷基、环烷基、烯基、炔基或未取代或取代的苄基，其制备方法，含有它们的试剂以及其用途。
• 3-Isoxazolylphenylverbindungen, ihre Herstellung und ihre Verwendung
  申请人：BASF Aktiengesellschaft

  公开号：EP0543238B1

  公开（公告）日：1997-06-04
• TRICYCLISCHE BENZOYLCYCLOHEXANDION-DERIVATE
  申请人：BASF AKTIENGESELLSCHAFT

  公开号：EP1181295A2

  公开（公告）日：2002-02-27
• KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：CHDI Foundation, Inc.

  公开号：US20180222838A1

  公开（公告）日：2018-08-09

  Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
• US5256666A
  申请人：——

  公开号：US5256666A

  公开（公告）日：1993-10-26